» Articles » PMID: 23142959

Low Dose Naloxone Attenuates the Pruritic but Not Anorectic Response to Rimonabant in Male Rats

Overview
Specialty Pharmacology
Date 2012 Nov 13
PMID 23142959
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Previous research suggests that the acute anorectic effect of cannabinoid CB1 receptor antagonist/inverse agonists may be secondary to response competition from the compulsive scratching and grooming syndrome characteristic of these agents.

Objectives: As the pruritic effect of rimonabant can be attenuated by the opioid receptor antagonist naloxone, these studies test the prediction that naloxone co-treatment should prevent acute rimonabant anorexia.

Methods: Two experiments comprehensively profiled the behavioural effects of an anorectic dose of rimonabant (1.5 mg/kg) in the absence or presence of naloxone (experiment 1: 0.01 or 0.1 mg/kg; experiment 2: 0.05 mg/kg).

Results: In both experiments, rimonabant not only significantly suppressed food intake and time spent eating but also induced compulsive scratching and grooming. In experiment 1, although the lower dose of naloxone seemed to weakly attenuate the effects of rimonabant both on ingestive and compulsive behaviours, the higher dose more strongly suppressed the compulsive elements but did not significantly affect the anorectic response. The results of experiment 2 showed that naloxone at a dose which markedly attenuated rimonabant-induced grooming and scratching did not alter the effects of the compound on food intake or time spent feeding. The apparent independence of the ingestive and compulsive effects of rimonabant was confirmed by the observation that despite a 'normalising' effect of naloxone co-treatment on behavioural structure (BSS), the opioid antagonist did not impact the suppressant effect of rimonabant on peak feeding.

Conclusion: The acute anorectic response to rimonabant would not appear to be secondary to compulsive scratching and grooming.

Citing Articles

A preclinical model of THC edibles that produces high-dose cannabimimetic responses.

English A, Uittenbogaard F, Torrens A, Sarroza D, Slaven A, Piomelli D Elife. 2024; 12.

PMID: 38214701 PMC: 10945583. DOI: 10.7554/eLife.89867.


Early Resveratrol Treatment Mitigates Joint Degeneration and Dampens Pain in a Mouse Model of Pseudoachondroplasia (PSACH).

Hecht J, Veerisetty A, Patra D, Hossain M, Chiu F, Mobed C Biomolecules. 2023; 13(10).

PMID: 37892235 PMC: 10605626. DOI: 10.3390/biom13101553.


CB1 antagonism produces behaviors more consistent with satiety than reduced reward value in food-maintained responding in rats.

Thompson E, Jagielo-Miller J, Vemuri V, Makriyannis A, McLaughlin P J Psychopharmacol. 2016; 30(5):482-91.

PMID: 27005309 PMC: 5531753. DOI: 10.1177/0269881116639287.


Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459.

Goonawardena A, Plano A, Robinson L, Ross R, Greig I, Pertwee R Behav Pharmacol. 2014; 26(3):289-303.

PMID: 25356730 PMC: 4445652. DOI: 10.1097/FBP.0000000000000108.


Oleoylethanolamide: a novel potential pharmacological alternative to cannabinoid antagonists for the control of appetite.

Romano A, Coccurello R, Giacovazzo G, Bedse G, Moles A, Gaetani S Biomed Res Int. 2014; 2014:203425.

PMID: 24800213 PMC: 3996326. DOI: 10.1155/2014/203425.


References
1.
Chen W, Tang H, Liu H, Long L, Gong Z, Zheng J . Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models. Eur J Pharmacol. 2010; 637(1-3):178-85. DOI: 10.1016/j.ejphar.2010.03.040. View

2.
Gomez R, Navarro M, Ferrer B, Trigo J, Bilbao A, Del Arco I . A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci. 2002; 22(21):9612-7. PMC: 6758016. View

3.
Cies J, Giamalis J . Treatment of cholestatic pruritus in children. Am J Health Syst Pharm. 2007; 64(11):1157-62. DOI: 10.2146/ajhp060453. View

4.
Halford J, Boyland E, Blundell J, Kirkham T, Harrold J . Pharmacological management of appetite expression in obesity. Nat Rev Endocrinol. 2010; 6(5):255-69. DOI: 10.1038/nrendo.2010.19. View

5.
Tallett A, Blundell J, Rodgers J . Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation. Behav Pharmacol. 2007; 18(7):591-600. DOI: 10.1097/FBP.0b013e3282eff0a9. View